Effectiveness of implementing a decentralized delivery of hepatitis C virus treatment with direct-acting antivirals: A systematic review with meta-analysis

被引:15
|
作者
Castro, Rodolfo [1 ,2 ]
Perazzo, Hugo [3 ]
Artilles Mello Mendonca de Araujo, Leticia [1 ]
Gutierres, Isabella Goncalves [1 ]
Grinsztejn, Beatriz [3 ]
Veloso, Valdilea G. [3 ]
机构
[1] Fundacao Oswaldo Cruz, Escola Nacl Saude Publ Sergio Arouca, Rio De Janeiro, RJ, Brazil
[2] Univ Fed Estado Rio de Janeiro, Inst Saude Colet, Rio De Janeiro, RJ, Brazil
[3] Fundacao Oswaldo Cruz, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, Brazil
来源
PLOS ONE | 2020年 / 15卷 / 02期
关键词
REAL-WORLD; CARE; SOFOSBUVIR; SAFETY; REGIMENS; THERAPY; PROGRAM;
D O I
10.1371/journal.pone.0229143
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Direct-acting agents (DAAs) for hepatitis C virus (HCV) treatment are safe and highly effective. Few studies described the sustained virologic response rates of treatment conducted by non-specialists. We performed a systematic review and meta-analysis to evaluate the effectiveness of decentralized strategies of HCV treatment with DAAs. PubMed, Embase, Scopus and LILACS were searched until March-2019. Studies were screened by two researchers according to the following inclusion criteria: HCV treatment using DAAs on real-life cohort studies or clinical trials conducted by non-specialized health personnel. The primary endpoint was the sustained virologic response rate at week 12 after the end-of-treatment (SVR12), which is binary at the patient level. Data were extracted in duplicate using electronic-forms and quality appraisal was performed with the NIH Quality Assessment Tool. Heterogeneity was assessed by I-2 statistics. Random-effects meta-analysis models were used for pooling SVR12 rates. Publication bias was assessed using funnel plots. Among the 130 selected studies, nine papers were included for quantitative synthesis. The quality-appraisal was good for two, fair for three and poor for four studies. The pooled relative risk (RR) of SVR12 was not statistically different between decentralized strategy and treatment by specialists [RR = 1.05; 95% confidence interval (95% CI): 0.98-1.1; I-2 = 45% (95% CI: 0-84%), p = 0.145]. SVR12 rate for decentralized HCV treatment was 81% [SVR12 95% CI: 72-89%; I-2 = 93% (95% CI: 88-96%)] and 95% [SVR12 95%CI: 92-98%; I-2 = 77% (95% CI: 52-89%)] with intention to treat analysis and per-protocol analysis, respectively. SVR12 rates using DAAs managed by non-specialized health personnel were satisfactory and similar to those obtained by specialists. This new delivery strategy can improve access to HCV treatment, especially in resource-limited settings.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD
    Balk, Ethan M.
    Adam, Gaelen P.
    Jadoul, Michel
    Martin, Paul
    Gordon, Craig E.
    [J]. KIDNEY INTERNATIONAL REPORTS, 2023, 8 (02): : 240 - 253
  • [22] Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patients
    Abad, Soraya
    Vega, Almudena
    Rincon, Diego
    Hernandez, Eduardo
    Merida, Evangelina
    Macias, Nicolas
    Munoz, Raquel
    Milla, Monica
    Luno, Jose
    Manuel Lopez-Gomez, Juan
    [J]. NEFROLOGIA, 2017, 37 (02): : 158 - 163
  • [23] Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis
    Muecke, Marcus M.
    Backus, Lisa I.
    Muecke, Victoria T.
    Coppola, Nicola
    Preda, Carmen M.
    Yeh, Ming-Lun
    Tang, Lydia S. Y.
    Belperio, Pamela S.
    Wilson, Eleanor M.
    Yu, Ming-Lung
    Zeuzem, Stefan
    Herrmann, Eva
    Vermehren, Johannes
    [J]. LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (03): : 172 - 180
  • [24] Cutaneous Adverse Events in Chronic Hepatitis C Patients Treated With New Direct-Acting Antivirals: A Systematic Review and Meta-Analysis
    Patel, Parth
    Malik, Kunal
    Krishnamurthy, Karthik
    [J]. JOURNAL OF CUTANEOUS MEDICINE AND SURGERY, 2016, 20 (01) : 58 - 66
  • [25] Direct-Acting Antivirals for HCV Treatment in Decompensated Liver Cirrhosis Patients: A Systematic Review and Meta-Analysis
    An, JiHyun
    Park, Dong Ah
    Ko, Min Jung
    Ahn, Sang Bong
    Yoo, Jeong-Ju
    Jun, Dae Won
    Yim, Sun Young
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (09):
  • [26] Direct-acting antivirals for hepatitis C treatment: effectiveness versus cost-effectiveness
    Chhatwal, Jagpreet
    [J]. FUTURE VIROLOGY, 2015, 10 (08) : 929 - 932
  • [27] Measure of adherence to direct-acting antivirals as a predictor of the effectiveness of hepatitis C treatment
    María Ángeles Campos Fernández de Sevilla
    Marta Gallego Úbeda
    Maria Tovar Pozo
    Emilio García-Cabrera
    Beatriz Monje García
    Federico Tutau Gómez
    Laura Delgado Téllez de Cepeda
    Irene Iglesias-Peinado
    [J]. International Journal of Clinical Pharmacy, 2019, 41 : 1545 - 1554
  • [28] Measure of adherence to direct-acting antivirals as a predictor of the effectiveness of hepatitis C treatment
    Campos Fernandez de Sevilla, Maria Angeles
    Gallego Ubeda, Marta
    Tovar Pozo, Maria
    Garcia-Cabrera, Emilio
    Monje Garcia, Beatriz
    Tutau Gomez, Federico
    Delgado Tellez de Cepeda, Laura
    Iglesias-Peinado, Irene
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2019, 41 (06) : 1545 - 1554
  • [29] Systematic review: cost-effectiveness of direct-acting antivirals for treatment of hepatitis C genotypes 2-6
    He, T.
    Lopez-Olivo, M. A.
    Hur, C.
    Chhatwal, J.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2017, 46 (08) : 711 - 721
  • [30] Direct-Acting Antivirals and the Risk of Hepatitis B Reactivation in Hepatitis B and C Co-Infected Patients: A Systematic Review and Meta-Analysis
    Oh, Joo Hyun
    Park, Dong Ah
    Ko, Min Jung
    Yoo, Jeong-Ju
    Yim, Sun Young
    Ahn, Ji-Hyun
    Jun, Dae Won
    Ahn, Sang Bong
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2022, 12 (12):